GleamWall
中文EN

HRTX HERON THERAPEUTICS, INC. /DE/

Pharmaceutical Preparations · Nasdaq · SEC CIK 818033 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-4.4%
TTM net income YoY-58.8%
TTM EPS YoY-22.2%
Revenue 3-yr CAGR6.5%
Net income 3-yr CAGR—

Margins

Gross margin71.5%
Operating margin-5.7%
Net margin-14.5%
FCF margin-9.7%
EBITDA margin-4.4%

Returns

ROE-217.8%
ROA-9.0%
ROIC (approx.)—
Asset turnover0.62x

Leverage & solvency

Liabilities / assets97.9%
Debt / equity0.00x
Current ratio2.33x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.64x
Accruals ratio-3.3%
Payout ratio—
Capex / revenue0.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$35.25M$37.67M$34.71M$40.59M$38.21M$37.20M$38.90M$40.78M
Cost of revenue$8.96M$11.57M$10.64M$11.12M$11.91M$9.86M$8.46M$10.23M
Gross profit$26.29M$26.09M$24.07M$29.47M$26.30M$27.34M$30.45M$30.55M
R&D expense$3.10M$2.70M$2.38M$3.75M$3.47M$2.93M$2.28M$3.18M
SG&A expense$12.34M$11.28M$12.14M$13.45M$13.98M$14.47M$12.70M$12.14M
Operating income-$1.67M-$2.04M-$4.76M$38,000-$4.09M-$1.64M$3.15M$4.17M
Net income-$5.01M-$5.49M-$8.11M-$2.95M-$17.50M-$2.38M$2.63M$3.66M
EBITDA-$1.28M-$1.59M-$4.24M$575,000-$3.48M-$1.03M$3.71M$4.75M
EPS (basic)-0.03-0.03-0.04—-0.10-0.020.02—
EPS (diluted)-0.03-0.03-0.04—-0.10-0.020.01—
Weighted avg. shares (diluted)190.92M190.34M189.65M—170.35M154.02M196.92M—
Balance sheet
Cash & equivalents$11.60M$20.72M$26.12M$28.65M$43.07M$16.52M$19.27M$25.80M
Short-term investments$11.85M$21.94M$18.67M$17.98M$12.42M$24.12M$31.41M$33.48M
Receivables$86.73M$89.57M$83.69M$89.59M$81.05M$79.93M$78.74M$78.88M
Inventory$91.30M$90.58M$92.54M$92.75M$70.03M$72.97M$56.93M$53.16M
Current assets$209.11M$229.84M$228.98M$238.07M$229.40M$210.92M$212.84M$209.01M
PP&E, net$11.08M$11.81M$12.03M$12.40M$12.96M$13.68M$14.54M$14.86M
Total assets$230.45M$252.26M$246.22M$255.88M$248.95M$232.09M$235.75M$233.15M
Current liabilities$89.85M$92.14M$90.52M$96.10M$89.71M$258.60M$88.56M$91.46M
Total liabilities$225.53M$245.35M$237.08M$241.54M$234.06M$259.35M$264.20M$266.80M
Shareholders' equity$4.92M$6.91M$9.14M$14.33M$14.88M-$27.26M-$28.45M-$33.65M
Shares outstanding———188.31M———152.13M
Cash flow statement
Operating cash flow-$794,000-$2.21M-$1.54M-$9.18M$1.33M-$10.87M-$8.87M-$11.78M
Capital expenditure$102,000$138,000$391,000$0$0$208,000$109,000$638,000
Free cash flow-$896,000-$2.35M-$1.93M-$9.18M$1.33M-$11.08M-$8.98M-$12.42M
Investing cash flow$10.09M-$3.27M-$939,000-$5.46M$11.86M$7.33M$2.27M$11.42M
Financing cash flow-$18.43M$82,000-$51,000$219,000$13.36M$781,000$64,000$423,000
Depreciation & amortization$391,000$452,000$529,000$537,000$615,000$611,000$551,000$581,000
Stock-based compensation$3.08M$3.18M$2.98M$2.18M$2.85M$2.80M$2.51M$2.29M

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.